Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

By sjmartinez • March 28, 2025

Aggarwal RR, Vuky J, VanderWeele D, Rettig M, Heath EI, Quigley D, Huang J, Chumber A, Cheung A, Foye A, Leung S, Abbey J, Dorr A, Nasoff M, Hunter J, Wang S, Flavell RR, Fong L, Liu B, Small EJ. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2025 Mar 26:JCO2401989. doi: 10.1200/JCO-24-01989. Epub ahead of print. PMID: 40138611.

Tags: Hematology/Oncology, Publications, Veterans Administration

Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation

Hu R, Tran B, Li S, Stackpole ML, Zeng W, Zhou Y, Melehy A, Sadeghi S, Finn RS, Zhou XJ, Li W, Agopian VG. Noninvasive[...]

Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA

Vidula N, Blouch E, Hesler K, Niemierko A, Bardia A. Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA. Breast[...]

Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura

Dommaraju SR, Shodiya M, Henick K. Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura. Cureus. 2025 Mar 18;17(3):e80781.[...]